Houston Methodist Research Institute, 6670 Bertner Ave, Houston, TX 77030, USA.
Houston Methodist Research Institute, 6670 Bertner Ave, Houston, TX 77030, USA.
J Infect. 2018 Oct;77(4):283-290. doi: 10.1016/j.jinf.2018.02.009. Epub 2018 Apr 9.
To develop and validate a simple prognostic scoring system to predict the mortality risk during treatment in tuberculosis patients.
Using data from the CDC's Tuberculosis Genotyping Information Management System of TB patients in Texas reported from 01/2010 to 12/2016, age ≥ 15 years and having an outcome as "completed" or "died", we developed and validated a prognostic mortality scoring system-based logistic regression beta-coefficients.
The developmental and validation cohorts consisted of 3378 and 3377 patients, respectively. The score used 9 demographic and clinical characteristics, which are usually available at the patient's initial visits to a healthcare facility. Prognostic scores were categorized into three groups that predicted mortality: low-risk (<15 points), medium-risk (15-18 points), and high-risk (>18 points). The model had excellent discrimination and calibration with an area under the receiver operating characteristic curve of 0.82 and 0.80, and a non-significant Hosmer-Lemeshow test P = 0.514 and P = 0.613 in the developmental and validation cohorts, respectively.
Our validated TB prognostic scoring system, which used demographic and clinical characteristics available at the patient's initial visits, can be a practical tool for health care providers to identify TB patients with high mortality risk so that appropriate treatment, medical supports and follow-up resources could be appropriately allocated.
开发并验证一种简单的预后评分系统,以预测结核病患者治疗期间的死亡风险。
利用美国疾病预防控制中心(CDC)的结核病基因分型信息管理系统(TBGenotype)中 2010 年 1 月至 2016 年 12 月德克萨斯州结核病患者的数据,纳入年龄≥15 岁且结局为“完成”或“死亡”的患者,我们开发并验证了一种基于预后死亡评分系统的逻辑回归β系数。
发展和验证队列分别包括 3378 例和 3377 例患者。该评分使用了 9 个人口统计学和临床特征,这些特征通常在患者首次就诊时就可获得。预后评分分为三组,预测死亡率:低危(<15 分)、中危(15-18 分)和高危(>18 分)。该模型具有出色的区分度和校准度,在发展和验证队列中的受试者工作特征曲线下面积分别为 0.82 和 0.80,Hosmer-Lemeshow 检验不显著(P=0.514 和 P=0.613)。
我们验证的结核病预后评分系统使用了患者首次就诊时可获得的人口统计学和临床特征,可作为医疗保健提供者识别高死亡率结核病患者的实用工具,以便适当分配治疗、医疗支持和随访资源。